FDA facility fees to rise for makers of generics, APIs

08/6/2013 | In-PharmaTechnologist.com

The FDA has announced that facility fees paid by U.S. and foreign manufacturers of generic drugs will go up by more than $40,000 next year, while the fees for makers of active pharmaceutical ingredients will go up by more than $8,000. Submission fees also will rise for abbreviated new drug applications, drug master files and prior approval supplements.

View Full Article in:

In-PharmaTechnologist.com

Published in Briefs: